LABA/LAMA vs LABA plus inhaled corticosteroid (ICS): Pneumonia
Long‐acting muscarinic antagonist (LAMA) plus long‐acting… leads to lower pneumonia compared with LABA plus inhaled corticosteroid (ICS) (high certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) vs LABA plus inhaled corticosteroid (ICS) Pneumonia · people with stable COPD Long‐acting muscarinic antagonist (LAMA) plus long‐acting… leads to lower pneumonia compared with LABA plus inhaled corticosteroid (ICS) (high certainty). Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled… (2023) · Cochrane Headline outcomes only | OR 0.61 [0.52, 0.72] | 14 studies · 21829 participants | High |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable… 2023 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.